HealthcareServices

Locally Advanced Pancreatic Cancer Market Forecast: How Big Will It Be by 2030?

February 26, 2026February 26, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the locally advanced pancreatic cancer market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Locally Advanced Pancreatic Cancer Market from 2026 to 2030?

The market for locally advanced pancreatic cancer has experienced rapid expansion over recent years. Projections indicate its size will increase from $1.05 billion in 2025 to $1.16 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.5%. Factors contributing to its historical growth include the frequent late-stage diagnosis of pancreatic cancer, restricted surgical options for locally advanced instances, a past dependence on gemcitabine-based chemotherapy, low overall survival rates, and the expansion of hospital-based oncology services.

The market size for locally advanced pancreatic cancer is projected to experience swift expansion in the coming years. This market is anticipated to reach $1.71 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.2%. This anticipated growth is largely due to the wider application of combination therapy protocols, the increasing use of SBRT, a surge in investment dedicated to pancreatic cancer research, a heightened focus on individualized oncology care, and the growing accessibility of specialized treatment centers. Key trends expected during this period encompass the increased deployment of combination chemotherapy regimens, the growing embrace of neoadjuvant treatment strategies, an elevated focus on reducing tumor size for surgical qualification, the broadened application of radiation therapy for localized disease management, and an escalating emphasis on comprehensive multidisciplinary treatment planning.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp

What Drivers Are Affecting Demand In The Locally Advanced Pancreatic Cancer Market?

The projected expansion of the locally advanced pancreatic cancer markets is anticipated due to the rising trend in tobacco consumption. Tobacco, derived from a plant, is utilized in products like cigarettes and cigars. This substance contains nicotine, an addictive compound associated with severe health problems including cancer and heart disease. Various elements contribute to the increasing use of tobacco, such as its widespread availability, economic accessibility, promotional strategies, societal tolerance in certain regions, and smoking induced by stress. It acts as a major risk factor for the emergence of locally advanced pancreatic cancer, exacerbating the occurrence of pancreatic malignancies. An illustrative example comes from a study released in October 2024 by the European Respiratory Society’s (ERS), a non-profit organization based in Switzerland. This research on smoking patterns among youth indicated a notable surge in smoking prevalence, with 22.5% of individuals smoking in 2022 rising to 40.1% in 2024. Consequently, the expanding tobacco consumption is propelling the expansion of the locally advanced pancreatic cancer market.

Which Segment Groups Are Influencing The Locally Advanced Pancreatic Cancer Market?

The locally advanced pancreatic cancer market covered in this report is segmented –

1) By Therapy: Chemotherapy, Radiation Therapy

2) By Route Of Administration: Oral, Injectables, Other Routes Of Administrations

3) By End-User: Hospital, Specialty Clinics, Research Institutions, Other End-Users

Subsegments:

1) By Chemotherapy: Gemcitabine-based Chemotherapy, FOLFIRINOX Chemotherapy

2) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy (SBRT)

What Industry Trends Are Transforming The Locally Advanced Pancreatic Cancer Market?

Major companies operating within the locally advanced pancreatic cancer market are prioritizing the development of innovative products, including orphan drugs, to improve treatment options, elevate patient outcomes, and address the unmet medical needs linked to this aggressive disease. Orphan drugs are specifically designed to treat rare conditions affecting a small number of individuals and are incentivized by regulatory bodies with advantages such as tax reductions and market exclusivity to promote their creation. For instance, in January 2025, Actuate Therapeutics Inc., a biopharmaceutical company located in the US, announced that its compound Elraglusib, a novel GSK-3ß inhibitor, received Orphan Drug Designation from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for treating pancreatic ductal adenocarcinoma (PDAC), a potential type of locally advanced pancreatic cancer. This designation highlights its potential to bridge a critical gap in the treatment of this severe cancer, particularly following encouraging Phase 2 trial results that showed significant clinical improvements and anti-tumor effects in metastatic PDAC patients.

Who Are The Prominent Global Companies Shaping The Locally Advanced Pancreatic Cancer Market Landscape?

Major companies operating in the locally advanced pancreatic cancer market are Pfizer Inc, F Hoffmann La Roche Ltd, Merck and Co Inc, Bristol Myers Squibb Company, AstraZeneca plc, AbbVie Inc, Novartis AG, GSK plc, Bayer AG, Eli Lilly and Company, Ipsen, Takeda Pharmaceutical Company Limited, Amgen Inc, Sanofi, Servier, NovoCure Limited, Halozyme Therapeutics, Clovis Oncology, Astellas Pharma, BeiGene

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/locally-advanced-pancreatic-cancer-global-market-report

Which Region Is Projected To Lead The Locally Advanced Pancreatic Cancer Market During The Forecast Period?

North America was the largest region in the locally advanced pancreatic cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Locally Advanced Pancreatic Cancer Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21214&type=smp

Browse Through More Reports Similar to the Global Locally Advanced Pancreatic Cancer Market 2026, By The Business Research Company

Gastroesophageal Junction Adenocarcinoma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroesophageal-junction-adenocarcinoma-therapeutics-global-market-report

Invasive Ductal Carcinoma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/invasive-ductal-carcinoma-therapeutics-global-market-report

Pancreatic Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795